@article{44be4c2e0cc04d7fb03d391d9b16ac7f,
title = "APASL consensus statements and recommendation on treatment of hepatitis C",
abstract = "The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the “APASL consensus statements and recommendation on management of hepatitis C” in March, 2015, in order to revise “APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409–435, 2012)”. The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.",
keywords = "APASL, DAAs, HCV, Interferon-free, Turkey",
author = "Masao Omata and Tatsuo Kanda and Lai Wei and Yu, {Ming Lung} and Chuang, {Wang Long} and Alaaeldin Ibrahim and Lesmana, {C. Rinaldi} and Jose Sollano and Manoj Kumar and Ankur Jindal and Sharma, {Barjesh Chander} and Hamid, {Saeed S.} and Dokmeci, {A. Kadir} and Mamun-Al-Mahtab and McCaughan, {Geofferey W.} and Jafri Wasim and Crawford, {Darrell H.G.} and Kao, {Jia Horng} and Osamu Yokosuka and Lau, {George K.K.} and Sarin, {Shiv Kumar}",
note = "Funding Information: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. This article does not contain any studies with animal subjects. Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Mamun Al-Mahtab, Alaaeldin Ibrahim, George K. K.Lau, Barjesh C. Sharma, Jose Sollano, Manoj Kumar, Ankur Jindal, A. Kadir Dokmeci, Geofferey W. McCaughan, Darrell HG Crawford, Jafri Wasim, and Shiv Kumar Sarin declare that they have no conflict of interest. Masao Omata received fees for being a speaker, consultant, and advisory board member for Bayer Co, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp & Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, and Zeria. Tatsuo Kanda received lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Daiichi-Sankyo, Bristol-Myers Squibb, Gilead Sciences and Abbvie, and a research grant from Chugai and MSD. Lai Wei has research grants from BMS and Roche, and consulting fee from Abbott, Abbvie, BMS, Gilead and Novartis. Ming-Lung Yu is the consultant, advise board member and have grant support from Abbvie, BMS, Gilead, ROCHE, MSD and Abbott. Wang-Long Chuang has speaker fees from Gilead, BMS, MSD, Roche and Novartis, and is a member of Advisory Board: Gilead, Abbvie and Roche. Saeed S. Hamid has conference travel support from Gilead. Jia-Horng Kao has served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences and Roche, and has also served on speaker{\textquoteright}s bureaus for Roche, Bristol-Myers Squibb, Gilead Sciences, and Novartis. Osamu Yokosuka has research grants from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, and Bristol-Myers Squibb, and received speakers fees from Merck Sharp & Dohme, Kowa Souku, Sysmex, Chugai Pharmaceutical Co, GlaxoSmithKline, Bristol-Myers Squibb, Ajinomoto-Seiyaku, Bayer, Abbott, Given Imaging, Mitsubishi Tanabe Pharm, Taiho Yakuhin, Dainippon Sumitomo Pharm, and Igaku-Seibutsugaku Institute. Publisher Copyright: {\textcopyright} 2016, The Author(s).",
year = "2016",
month = sep,
day = "1",
doi = "10.1007/s12072-016-9717-6",
language = "English",
volume = "10",
pages = "702--726",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "5",
}